Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.

  • 1.

    AquinoVMHerreraLSandlerESBuchananGR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer2000;88:17101714.

    • Search Google Scholar
    • Export Citation
  • 2.

    FreifeldAGWalshTMarshallD. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol1995;13:165176.

    • Search Google Scholar
    • Export Citation
  • 3.

    HidalgoMHornedoJLumbrerasC. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer1999;85:213219.

    • Search Google Scholar
    • Export Citation
  • 4.

    HughesWTArmstrongDBodeyGP. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis2002;34:730751.

    • Search Google Scholar
    • Export Citation
  • 5.

    KernWVComettaADe BockR. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med1999;341:312318.

    • Search Google Scholar
    • Export Citation
  • 6.

    MalikIAAbbasZKarimM. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet1992;339:10921096.

    • Search Google Scholar
    • Export Citation
  • 7.

    PizzoPA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med1993;328:13231332.

  • 8.

    RolstonKVRubensteinEBFreifeldA. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am1996;10:223237.

    • Search Google Scholar
    • Export Citation
  • 9.

    SchimpffSC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med1986;80:1320.

  • 10.

    TalcottJAFinbergRMayerRJGoldmanL. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med1988;148:25612568.

    • Search Google Scholar
    • Export Citation
  • 11.

    TalcottJASiegelRDFinbergRGoldmanL. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol1992;10:316322.

    • Search Google Scholar
    • Export Citation
  • 12.

    TalcottJAWhalenAClarkJ. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol1994;12:107114.

    • Search Google Scholar
    • Export Citation
  • 13.

    MihuCNSchaubJKeshS. Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study. Biol Blood Marrow Transplant2008;14:14291433.

    • Search Google Scholar
    • Export Citation
  • 14.

    NeofytosDHornDAnaissieE. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) alliance registry. Clin Infect Dis2009;48:265273.

    • Search Google Scholar
    • Export Citation
  • 15.

    RizzoJDWingardJRTichelliA. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant2006;12:138151.

    • Search Google Scholar
    • Export Citation
  • 16.

    SullivanKMDykewiczCALongworthDL. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation practice guidelines and beyond. Hematology Am Soc Hematol Educ Program2001:392421.

    • Search Google Scholar
    • Export Citation
  • 17.

    FreifeldAGBowEJSepkowitzKA. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis2011;52:e5693.

    • Search Google Scholar
    • Export Citation
  • 18.

    RotsteinCBowEJLaverdiereM. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis1999;28:331340.

    • Search Google Scholar
    • Export Citation
  • 19.

    GoodmanJLWinstonDJGreenfieldRA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 20.

    SlavinMAOsborneBAdamsR. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 21.

    MarrKASeidelKSlavinMA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood2000;96:20552061.

    • Search Google Scholar
    • Export Citation
  • 22.

    KernWBehreGRudolfT. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer1998;83:291301.

    • Search Google Scholar
    • Export Citation
  • 23.

    WinstonDJChandrasekarPHLazarusHM. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med1993;118:495503.

    • Search Google Scholar
    • Export Citation
  • 24.

    WingardJRCarterSLWalshTJ. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood2010;116:51115118.

    • Search Google Scholar
    • Export Citation
  • 25.

    VazquezJASkiestDJNietoL. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis2006;42:11791186.

    • Search Google Scholar
    • Export Citation
  • 26.

    CornelyOAMaertensJWinstonDJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med2007;356:348359.

    • Search Google Scholar
    • Export Citation
  • 27.

    UllmannAJLiptonJHVesoleDH. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med2007;356:335347.

    • Search Google Scholar
    • Export Citation
  • 28.

    Astellas Pharma. Prescribing information. Cresemba (isavuconazonium sulfate) capsules and intravenous use. 2015. Available at: http://www.astellas.us/docs/cresemba.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 29.

    MaertensJARaadIIMarrKA. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet2016;387:760769.

    • Search Google Scholar
    • Export Citation
  • 30.

    MarrKACrippaFLeisenringW. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood2004;103:15271533.

    • Search Google Scholar
    • Export Citation
  • 31.

    MarrKALeisenringWCrippaF. Cyclophosphamide metabolism is affected by azole antifungals. Blood2004;103:15571559.

  • 32.

    US Food and Drug Administration. Isavuconazonium – invasive aspergillosis and invasive mucormycosis. Advisory Committee briefing document. 2015. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm430748.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 33.

    YapYGCammAJ. Drug induced QT prolongation and torsades de pointes. Heart2003;89:13631372.

  • 34.

    U.S. Food and Drug Administration. Prescribing information. Sporanox (itraconazole) capsules. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020083s053lbl.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 35.

    AndesDvan OgtropM. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother1999;43:21162120.

    • Search Google Scholar
    • Export Citation
  • 36.

    BrammerKWFarrowPRFaulknerJK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis1990;12(Suppl 3):S318326.

    • Search Google Scholar
    • Export Citation
  • 37.

    ClancyCJYuVLMorrisAJ. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother2005;49:31713177.

    • Search Google Scholar
    • Export Citation
  • 38.

    CsajkaCDecosterdLABuclinT. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol2001;57:723727.

    • Search Google Scholar
    • Export Citation
  • 39.

    RexJHPfallerMAGalgianiJN. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis1997;24:235247.

    • Search Google Scholar
    • Export Citation
  • 40.

    US Food and Drug Administration. Prescribing information. Diflucan (fluconazole) tablets oral suspension and intravenous use. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 41.

    KrishnaGMotonAMaL. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother2009;53:958966.

    • Search Google Scholar
    • Export Citation
  • 42.

    US Food and Drug Administration. Prescribing information. Noxafil (posaconazole) oral suspension delayed-release tablet intravenous use. 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 43.

    GrossBNIhorstGJungM. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy2013;33:11171125.

    • Search Google Scholar
    • Export Citation
  • 44.

    BryantAMSlainDCumpstonACraigM. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents2011;37:266269.

    • Search Google Scholar
    • Export Citation
  • 45.

    BruggemannRJTouwDJAarnoutseRE. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother2009;53:303305.

    • Search Google Scholar
    • Export Citation
  • 46.

    KraftWKChangPSvan IerselML. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother2014;58:40204025.

    • Search Google Scholar
    • Export Citation
  • 47.

    HeinzWJEgererGLellekH. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses2013;56:304310.

    • Search Google Scholar
    • Export Citation
  • 48.

    MaertensJCornelyOAUllmannAJ. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother2014;58:36103617.

    • Search Google Scholar
    • Export Citation
  • 49.

    JangSHColangeloPMGobburuJV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther2010;88:115119.

    • Search Google Scholar
    • Export Citation
  • 50.

    ToniniJThiebautAJourdilJF. Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother2012;56:52475252.

    • Search Google Scholar
    • Export Citation
  • 51.

    ShieldsRKClancyCJVadnerkarA. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother2011;55:13081311.

    • Search Google Scholar
    • Export Citation
  • 52.

    EidenCMenianeJCPeyriereH. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis2012;31:161167.

    • Search Google Scholar
    • Export Citation
  • 53.

    HoeniglMRaggamRBSalzerHJ. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents2012;39:510513.

    • Search Google Scholar
    • Export Citation
  • 54.

    LebeauxDLanternierFElieC. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother2009;53:52245229.

    • Search Google Scholar
    • Export Citation
  • 55.

    HowardSJCerarDAndersonMJ. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis2009;15:10681076.

    • Search Google Scholar
    • Export Citation
  • 56.

    MavridouEBruggemannRJMelchersWJ. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother2010;54:860865.

    • Search Google Scholar
    • Export Citation
  • 57.

    BoogaertsMAVerhoefGEZacheeP. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses1989;32(Suppl 1):103108.

    • Search Google Scholar
    • Export Citation
  • 58.

    TricotGJoostenEBoogaertsMA. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis1987;9(Suppl 1):S9499.

    • Search Google Scholar
    • Export Citation
  • 59.

    GlasmacherAHahnCLeutnerC. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses1999;42:443451.

    • Search Google Scholar
    • Export Citation
  • 60.

    GlasmacherAHahnCMolitorE. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses1999;42:591600.

    • Search Google Scholar
    • Export Citation
  • 61.

    DenningDWTuckerRMHansonLH. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med1989;149:23012308.

  • 62.

    DenningDWTuckerRMHansonLHStevensDA. Treatment of invasive aspergillosis with itraconazole. Am J Med1989;86:791800.

  • 63.

    SharkeyPKRinaldiMGDunnJF. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother1991;35:707713.

  • 64.

    WheatJHafnerRKorzunAH. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med1995;98:336342.

    • Search Google Scholar
    • Export Citation
  • 65.

    LestnerJMRobertsSAMooreCB. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis2009;49:928930.

    • Search Google Scholar
    • Export Citation
  • 66.

    BaroneJAMoskovitzBLGuarnieriJ. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy1998;18:295301.

    • Search Google Scholar
    • Export Citation
  • 67.

    PascualACalandraTBolayS. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis2008;46:201211.

    • Search Google Scholar
    • Export Citation
  • 68.

    JeansARHowardSJAl-NakeebZ. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother2012;56:51805185.

    • Search Google Scholar
    • Export Citation
  • 69.

    SmithJSafdarNKnasinskiV. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother2006;50:15701572.

  • 70.

    TrokePFHockeyHPHopeWW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother2011;55:47824788.

    • Search Google Scholar
    • Export Citation
  • 71.

    DoltonMJRayJEChenSC. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother2012;56:47934799.

    • Search Google Scholar
    • Export Citation
  • 72.

    MiyakisSvan HalSJRayJMarriottD. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect2010;16:927933.

    • Search Google Scholar
    • Export Citation
  • 73.

    Gomez-LopezACendejas-BuenoECuestaI. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Med Mycol2012;50:439445.

    • Search Google Scholar
    • Export Citation
  • 74.

    UedaKNannyaYKumanoK. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol2009;89:592599.

    • Search Google Scholar
    • Export Citation
  • 75.

    TrifilioSSinghalSWilliamsS. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant2007;40:451456.

    • Search Google Scholar
    • Export Citation
  • 76.

    MitsaniDNguyenMHShieldsRK. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother2012;56:23712377.

    • Search Google Scholar
    • Export Citation
  • 77.

    PascualACsajkaCBuclinT. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis2012;55:381390.

    • Search Google Scholar
    • Export Citation
  • 78.

    ZoniosDIGea-BanaclocheJChildsRBennettJE. Hallucinations during voriconazole therapy. Clin Infect Dis2008;47:e7e10.

  • 79.

    HamadaYSetoYYagoKKuroyamaM. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother2012;18:501507.

    • Search Google Scholar
    • Export Citation
  • 80.

    KimKHLeeSLeeS. Voriconazole-associated severe hyponatremia. Med Mycol2012;50:103105.

  • 81.

    MatsumotoKIkawaKAbematsuK. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents2009;34:9194.

    • Search Google Scholar
    • Export Citation
  • 82.

    PurkinsLWoodNKleinermansD. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol2003;56Suppl 1:1723.

    • Search Google Scholar
    • Export Citation
  • 83.

    Pfizer Inc.Prescribing information. Vfend (voriconazole) tablets oral suspension and intravenous use. 2015. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=618. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 84.

    AshbeeHRBarnesRAJohnsonEM. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother2014;69:11621176.

    • Search Google Scholar
    • Export Citation
  • 85.

    AndesDPascualAMarchettiO. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother2009;53:2434.

    • Search Google Scholar
    • Export Citation
  • 86.

    KohLPKurupAGohYT. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol2002;71:260267.

    • Search Google Scholar
    • Export Citation
  • 87.

    WinstonDJMaziarzRTChandrasekarPH. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med2003;138:705713.

    • Search Google Scholar
    • Export Citation
  • 88.

    BatesDWSuLYuDT. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int2001;60:14521459.

  • 89.

    WingardJRKubilisPLeeL. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis1999;29:14021407.

    • Search Google Scholar
    • Export Citation
  • 90.

    RijndersBJCornelissenJJSlobbeL. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis2008;46:14011408.

    • Search Google Scholar
    • Export Citation
  • 91.

    PerfectJR. Aerosolized antifungal prophylaxis: the winds of change?Clin Infect Dis2008;46:14091411.

  • 92.

    Espinel-IngroffA. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol2003;20:121136.

    • Search Google Scholar
    • Export Citation
  • 93.

    VillanuevaAArathoonEGGotuzzoE. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis2001;33:15291535.

    • Search Google Scholar
    • Export Citation
  • 94.

    MaertensJRaadIPetrikkosG. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis2004;39:15631571.

    • Search Google Scholar
    • Export Citation
  • 95.

    KartsonisNASaahAJJoy LipkaC. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect2005;50:196205.

    • Search Google Scholar
    • Export Citation
  • 96.

    U.S Food and Drug Administration. Prescribing information. Mycamine (micafungin sodium) for injection; IV infusion only. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021506s015lbl.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 97.

    van BurikJARatanatharathornVStepanDE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis2004;39:14071416.

    • Search Google Scholar
    • Export Citation
  • 98.

    YokoteTAkiokaTOkaS. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol2004;83:6466.

    • Search Google Scholar
    • Export Citation
  • 99.

    OtaSTanakaJKahataK. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol2004;79:390393.

    • Search Google Scholar
    • Export Citation
  • 100.

    SingerMSSeibelNLVezinaG. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol2003;25:252256.

    • Search Google Scholar
    • Export Citation
  • 101.

    KrauseDSSimjeeAEvan RensburgC. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis2004;39:770775.

    • Search Google Scholar
    • Export Citation
  • 102.

    VazquezJASchranzJAClarkK. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr2008;48:304309.

    • Search Google Scholar
    • Export Citation
  • 103.

    ReboliACRotsteinCPappasPG. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med2007;356:24722482.

  • 104.

    BodeyGPMardaniMHannaHA. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med2002;112:380385.

    • Search Google Scholar
    • Export Citation
  • 105.

    MarrKASeidelKWhiteTCBowdenRA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis2000;181:309316.

    • Search Google Scholar
    • Export Citation
  • 106.

    WeinbergerMElattarIMarshallD. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore)1992;71:2443.

    • Search Google Scholar
    • Export Citation
  • 107.

    WalshTJWhitcombPORevankarSGPizzoPA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer1995;76:23572362.

    • Search Google Scholar
    • Export Citation
  • 108.

    OffnerFCordonnierCLjungmanP. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis1998;26:10981103.

    • Search Google Scholar
    • Export Citation
  • 109.

    FukudaTBoeckhMGuthrieKA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant2004;10:494503.

    • Search Google Scholar
    • Export Citation
  • 110.

    MeyersJDFlournoyNThomasED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis1980;142:338346.

    • Search Google Scholar
    • Export Citation
  • 111.

    SaralRBurnsWHLaskinOL. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med1981;305:6367.

  • 112.

    SaralRAmbinderRFBurnsWH. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med1983;99:773776.

    • Search Google Scholar
    • Export Citation
  • 113.

    MackallCFryTGressR. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant2009;44:457462.

    • Search Google Scholar
    • Export Citation
  • 114.

    TomblynMChillerTEinseleH. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant2009;15:11431238.

    • Search Google Scholar
    • Export Citation
  • 115.

    ZaiaJBadenLBoeckhMJ. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant2009;44:471482.

  • 116.

    Genzyme Corporation. Prescribing information. Campath (alemtuzumab) injection for intravenous use. Cambridge, MA: Genzyme Corporation; 2009. Available at: http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 117.

    KeatingMCoutreSRaiK. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma2004;4:220227.

    • Search Google Scholar
    • Export Citation
  • 118.

    BoeckhMKimHWFlowersMED. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood2006;107:18001805.

    • Search Google Scholar
    • Export Citation
  • 119.

    ErardVGuthrieKAVarleyC. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood2007;110:30713077.

    • Search Google Scholar
    • Export Citation
  • 120.

    Asano-MoriYKandaYOshimaK. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol2008;83:472476.

    • Search Google Scholar
    • Export Citation
  • 121.

    OshimaKTakahashiTMoriT. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis2010;12:421427.

    • Search Google Scholar
    • Export Citation
  • 122.

    SchuchterLMWingardJRPiantadosiS. Herpes zoster infection after autologous bone marrow transplantation. Blood1989;74:14241427.

  • 123.

    Chanan-KhanASonneveldPSchusterMW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 124.

    ReeceDERodriguezGPChenC. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol2008;26:47774783.

    • Search Google Scholar
    • Export Citation
  • 125.

    TongYQianJLiY. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol2007;82:403404.

  • 126.

    VarettoniMVassalloCBorroniG. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol2007;86:301302.

    • Search Google Scholar
    • Export Citation
  • 127.

    Amgen Inc.Prescribing information: Kyprolis (carfilzomib) for intravenous injection. 2016. Available at: http://pi.amgen.com/united_states/kyprolis/kyprolis_pi.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 128.

    PourLAdamZBuresovaL. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma2009;9:151153.

    • Search Google Scholar
    • Export Citation
  • 129.

    VickreyEAllenSMehtaJSinghalS. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer2009;115:229232.

    • Search Google Scholar
    • Export Citation
  • 130.

    GeorgeBPatiNGilroyN. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis2010;12:322329.

    • Search Google Scholar
    • Export Citation
  • 131.

    BeckJCWagnerJEDeForTE. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant2010;16:215222.

    • Search Google Scholar
    • Export Citation
  • 132.

    MilanoFPergamSAXieH. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood2011;118:56895696.

    • Search Google Scholar
    • Export Citation
  • 133.

    MontesinosPSanzJCanteroS. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant2009;15:730740.

    • Search Google Scholar
    • Export Citation
  • 134.

    MeyersJDReedECSheppDH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med1988;318:7075.

    • Search Google Scholar
    • Export Citation
  • 135.

    PrenticeHGGluckmanEPowlesRL. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet1994;343:749753.

    • Search Google Scholar
    • Export Citation
  • 136.

    LjungmanPde La CamaraRMilpiedN. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood2002;99:30503056.

    • Search Google Scholar
    • Export Citation
  • 137.

    ReusserPEinseleHLeeJ. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood2002;99:11591164.

    • Search Google Scholar
    • Export Citation
  • 138.

    ReusserPGambertoglioJGLillebyKMeyersJD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis1992;166:473479.

    • Search Google Scholar
    • Export Citation
  • 139.

    BacigalupoATedoneEVan LintMT. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant1994;13:783788.

    • Search Google Scholar
    • Export Citation
  • 140.

    BreganteSBertilsonSTedoneE. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant2000;26:2329.

    • Search Google Scholar
    • Export Citation
  • 141.

    EinseleHReusserPBornhauserM. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood2006;107:30023008.

    • Search Google Scholar
    • Export Citation
  • 142.

    WinstonDJBadenLRGabrielDA. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant2006;12:635640.

    • Search Google Scholar
    • Export Citation
  • 143.

    AyalaEGreeneJSandinR. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant2006;37:851856.

    • Search Google Scholar
    • Export Citation
  • 144.

    BuscaAde FabritiisPGhisettiV. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis2007;9:102107.

    • Search Google Scholar
    • Export Citation
  • 145.

    van der HeidenPLKalpoeJSBargeRM. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant2006;37:693698.

    • Search Google Scholar
    • Export Citation
  • 146.

    KalilACFreifeldAGLydenERStonerJA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One2009;4:e5512.

    • Search Google Scholar
    • Export Citation
  • 147.

    KalilACMindruCBothaJF. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl2012;18:14401447.

    • Search Google Scholar
    • Export Citation
  • 148.

    Genentech Inc.Prescribing information. Valcyte (valganciclovir hydrochloride) tablets oral solution. 2015. Available at: http://www.gene.com/download/pdf/valcyte_prescribing.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 149.

    BosiABartolozziBVannucchiAM. Polymerase chain reaction-based “pre-emptive” therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica2002;87:446447.

    • Search Google Scholar
    • Export Citation
  • 150.

    ChakrabartiSCollinghamKEOsmanH. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant2001;28:879881.

    • Search Google Scholar
    • Export Citation
  • 151.

    LjungmanPDeliliersGLPlatzbeckerU. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood2001;97:388392.

    • Search Google Scholar
    • Export Citation
  • 152.

    PlatzbeckerUBandtDThiedeC. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation2001;71:880885.

    • Search Google Scholar
    • Export Citation
  • 153.

    NguyenQChamplinRGiraltS. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis1999;28:618623.

    • Search Google Scholar
    • Export Citation
  • 154.

    BoeckhMLeisenringWRiddellSR. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood2003;101:407414.

    • Search Google Scholar
    • Export Citation
  • 155.

    HakkiMRiddellSRStorekJ. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood2003;102:30603067.

    • Search Google Scholar
    • Export Citation
  • 156.

    LaurentiLPiccioniPCattaniP. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 157.

    MoretonPKennedyBLucasG. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol2005;23:29712979.

    • Search Google Scholar
    • Export Citation
  • 158.

    NguyenDDCaoTMDuganK. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma2002;3:105110.

    • Search Google Scholar
    • Export Citation
  • 159.

    O'BrienSRavandiFRiehlT. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood2008;111:18161819.

    • Search Google Scholar
    • Export Citation
  • 160.

    MontilloMSchinkoetheTElterT. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest2005;23:488496.

    • Search Google Scholar
    • Export Citation
  • 161.

    MorettiSZikosPVan LintMT. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant1998;22:175180.

    • Search Google Scholar
    • Export Citation
  • 162.

    US Food and Drug Administration. Prescribing information. Foscavir (foscarnet) for injection. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 163.

    Gilead Sciences Inc.Prescribing information. Vistide (cidofovir) injection. 2010. Available at: http://www.gilead.com/~/media/files/pdfs/medicines/other/vistide/vistide.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 164.

    O'BrienSMKeatingMJMocarskiES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma2006;7:125130.

    • Search Google Scholar
    • Export Citation
  • 165.

    LiangR. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood2009;113:31473153.

    • Search Google Scholar
    • Export Citation
  • 166.

    BrechotCDegosFLugassyC. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med1985;312:270276.

    • Search Google Scholar
    • Export Citation
  • 167.

    DhedinNDouvinCKuentzM. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation1998;66:616619.

    • Search Google Scholar
    • Export Citation
  • 168.

    BorentainPColsonPCosoD. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat2010;17:807815.

    • Search Google Scholar
    • Export Citation
  • 169.

    EvensAMJovanovicBDSuYC. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol2011;22:11701180.

    • Search Google Scholar
    • Export Citation
  • 170.

    FukushimaNMizutaTTanakaM. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol2009;20:20132017.

    • Search Google Scholar
    • Export Citation
  • 171.

    JiDCaoJHongX. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol2010;85:243250.

    • Search Google Scholar
    • Export Citation
  • 172.

    KooYXTanDSTanIB. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer2010;116:115121.

    • Search Google Scholar
    • Export Citation
  • 173.

    LalazarGRundDShouvalD. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol2007;136:699712.

    • Search Google Scholar
    • Export Citation
  • 174.

    LauGKKHeMLFongDY. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology2002;36:702709.

    • Search Google Scholar
    • Export Citation
  • 175.

    MatsueKKimuraSTakanashiY. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer2010;116:47694776.

    • Search Google Scholar
    • Export Citation
  • 176.

    YeoWChanPKZhongS. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol2000;62:299307.

    • Search Google Scholar
    • Export Citation
  • 177.

    YeoWChanTCLeungNW. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol2009;27:605611.

    • Search Google Scholar
    • Export Citation
  • 178.

    LiangRHLokASLaiCL. Hepatitis B infection in patients with lymphomas. Hematol Oncol1990;8:261270.

  • 179.

    DaiMSLuJJChenYC. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer2001;92:29272932.

  • 180.

    SteinbergJLYeoWZhongS. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol2000;60:249255.

    • Search Google Scholar
    • Export Citation
  • 181.

    GalbraithRMEddlestonALWilliamsRZuckermanAJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet1975;2:528530.

    • Search Google Scholar
    • Export Citation
  • 182.

    PintoPCHuEBernstein-SingerM. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer1990;65:878884.

    • Search Google Scholar
    • Export Citation
  • 183.

    YeoWChanPKHuiP. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol2003;70:553561.

    • Search Google Scholar
    • Export Citation
  • 184.

    YeoWHuiEPChanAT. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol2005;28:379384.

    • Search Google Scholar
    • Export Citation
  • 185.

    ViganoMVenerCLamperticoP. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant2011;46:125131.

    • Search Google Scholar
    • Export Citation
  • 186.

    HammondSPBorcheltAMUkomaduC. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2009;15:10491059.

    • Search Google Scholar
    • Export Citation
  • 187.

    RossiGPelizzariAMottaMPuotiM. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol2001;115:5862.

    • Search Google Scholar
    • Export Citation
  • 188.

    YeoWChanPKSHoWM. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol2004;22:927934.

    • Search Google Scholar
    • Export Citation
  • 189.

    ZiakasPDKarsaliakosPMylonakisE. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica2009;94:9981005.

    • Search Google Scholar
    • Export Citation
  • 190.

    GiacconeLFestucciaMMarengoA. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant2010;16:809817.

    • Search Google Scholar
    • Export Citation
  • 191.

    GishRG. Hepatitis B treatment: Current best practices, avoiding resistance. Cleve Clin J Med2009;76(Suppl 3):S1419.

  • 192.

    CortelezziAViganoMZilioliVR. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol2006;35:467469.

    • Search Google Scholar
    • Export Citation
  • 193.

    PetersMGHannHWMartinP. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology2004;126:91101.

    • Search Google Scholar
    • Export Citation
  • 194.

    MarcellinPHeathcoteEJButiM. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med2008;359:24422455.

    • Search Google Scholar
    • Export Citation
  • 195.

    KitrinosKMCorsaALiuY. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology2014;59:434442.

    • Search Google Scholar
    • Export Citation
  • 196.

    MarcellinPGaneEButiM. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet2013;381:468475.

    • Search Google Scholar
    • Export Citation
  • 197.

    LeungNPengCYHannHW. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology2009;49:7279.

    • Search Google Scholar
    • Export Citation
  • 198.

    ChanHLHeathcoteEJMarcellinP. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med2007;147:745754.

    • Search Google Scholar
    • Export Citation
  • 199.

    WatanabeMShibuyaATakadaJ. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med2010;21:333337.

    • Search Google Scholar
    • Export Citation
  • 200.

    LiuWPZhengWSongYQ. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. World J Gastroenterol2014;20:51655170.

    • Search Google Scholar
    • Export Citation
  • 201.

    TenneyDJRoseREBaldickCJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology2009;49:15031514.

    • Search Google Scholar
    • Export Citation
  • 202.

    HadziyannisSJTassopoulosNCHeathcoteEJ. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology2006;131:17431751.

    • Search Google Scholar
    • Export Citation
  • 203.

    HeathcoteEJMarcellinPButiM. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology2011;140:132143.

    • Search Google Scholar
    • Export Citation
  • 204.

    European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol2012;57:167185.

    • Search Google Scholar
    • Export Citation
  • 205.

    WangYThongsawatSGaneEJ. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat2013;20:e3746.

    • Search Google Scholar
    • Export Citation
  • 206.

    HaNBHaNBGarciaRT. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology2009;50:727734.

  • 207.

    IzzedineHHulotJSLaunay-VacherV. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int2004;66:11531158.

    • Search Google Scholar
    • Export Citation
  • 208.

    NelsonMRKatlamaCMontanerJS. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS2007;21:12731281.

    • Search Google Scholar
    • Export Citation
  • 209.

    LiawYFGaneELeungN. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology2009;136:486495.

    • Search Google Scholar
    • Export Citation
  • 210.

    GoncalvesJLaeufleRAvilaC. Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the novartis global database [abstract]. J Hepatol2009;50:Abstract 907.

    • Search Google Scholar
    • Export Citation
  • 211.

    ArtzASSomerfieldMRFeldJJ. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol2010;28:31993202.

    • Search Google Scholar
    • Export Citation
  • 212.

    LokASMcMahonBJ. Chronic hepatitis B: update 2009. Hepatology2009;50:661662.

  • 213.

    McQuillanGMTownsendTRJohannesCB. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am J Epidemiol1987;126:484491.

    • Search Google Scholar
    • Export Citation
  • 214.

    IOM. Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C: National Academies Press; 2010. Available at: http://www.cdc.gov/hepatitis/pdfs/iom-hepatitisandlivercancerreport.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 215.

    HatzakisAWaitSBruixJ. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat2011;18(Suppl 1):116.

    • Search Google Scholar
    • Export Citation
  • 216.

    WeinbaumCMWilliamsIMastEE. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep2008;57:120.

    • Search Google Scholar
    • Export Citation
  • 217.

    GhanyMGStraderDBThomasDLSeeffLB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009;49:13351374.

  • 218.

    LokASMcMahonBJ. Chronic hepatitis B. Hepatology2007;45:507539.

  • 219.

    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas v.3.2016. Available at: www.nccn.org. Accessed May 12 2016.

    • Search Google Scholar
    • Export Citation
  • 220.

    LeeMHYangHILuSN. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis2012;206:469477.

    • Search Google Scholar
    • Export Citation
  • 221.

    YaziciOSendurMAAksoyS. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol2014;20:67166724.

    • Search Google Scholar
    • Export Citation
  • 222.

    BorchardtRATorresHA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol2014;20:27712776.

  • 223.

    AASLD/IDSA: recommendations for testing managing and treating hepatitis C. Available at: www.hcvguidelines.org. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 224.

    Prevention CfDCa. HIV Surveillance Report. Vol. 25; 2013. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed June 22 2016.

    • Search Google Scholar
    • Export Citation
  • 225.

    ChiaoEYDezubeBJKrownSE. Time for oncologists to opt in for routine opt-out HIV testing?JAMA2010;304:334339.

  • 226.

    SilverbergMJChaoCLeydenWA. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev2011;20:25512559.

    • Search Google Scholar
    • Export Citation
  • 227.

    ShielsMSPfeifferRMGailMH. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst2011;103:753762.

  • 228.

    BiggarRJEngelsEALyS. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr2005;39:293299.

  • 229.

    YarchoanRTosatoGLittleRF. Therapy insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol2005;2:406415; quiz 423.

    • Search Google Scholar
    • Export Citation
  • 230.

    RudekMAFlexnerCAmbinderRF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol2011;12:905912.

  • 231.

    HwangJPGranwehrBPTorresHA. HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract2015;11:384390.

    • Search Google Scholar
    • Export Citation
  • 232.

    BransonBMHandsfieldHHLampeMA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep2006;55:117.

    • Search Google Scholar
    • Export Citation
  • 233.

    GrossAEBrysonML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother2015;49:11251135.

    • Search Google Scholar
    • Export Citation
  • 234.

    BeairdOEFreifeldAIsonMG. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis2016;18:210215.

    • Search Google Scholar
    • Export Citation
  • 235.

    HoelleinAHeckerJHoffmannD. Serious outbreak of human metapneumovirus in patients with hematologic malignancies. Leuk Lymphoma2016;57:623627.

    • Search Google Scholar
    • Export Citation
  • 236.

    GodetCLe GoffJBeby-DefauxA. Human metapneumovirus pneumonia in patients with hematological malignancies. J Clin Virol2014;61:593596.

    • Search Google Scholar
    • Export Citation
  • 237.

    ShahDPShahPKAzziJMChemalyRF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett2016;370:358364.

    • Search Google Scholar
    • Export Citation
  • 238.

    AnakSAtayDUnuvarA. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr Pulmonol2010;45:307311.

    • Search Google Scholar
    • Export Citation
  • 239.

    ChoiJHChoiEHKangHJ. Respiratory viral infections after hematopoietic stem cell transplantation in children. J Korean Med Sci2013;28:3641.

    • Search Google Scholar
    • Export Citation
  • 240.

    KhannaNWidmerAFDeckerM. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis2008;46:402412.

    • Search Google Scholar
    • Export Citation
  • 241.

    AsnerSStephensDPedullaP. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J2013;32:10731076.

    • Search Google Scholar
    • Export Citation
  • 242.

    LoMSLeeGMGunawardaneN. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant2013;17:133143.

    • Search Google Scholar
    • Export Citation
  • 243.

    WhimbeyEChamplinREEnglundJA. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant1995;16:393399.

    • Search Google Scholar
    • Export Citation
  • 244.

    MarcelinJRWilsonJWRazonableRR. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis2014;16:242250.

    • Search Google Scholar
    • Export Citation
  • 245.

    Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR Morb Mortality Wkly Rep2011;60:126.

    • Search Google Scholar
    • Export Citation
  • 246.

    FioreAEFryAShayD. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2011;60:124.

    • Search Google Scholar
    • Export Citation
  • 247.

    MandellLAWunderinkRGAnzuetoA. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis2007;44(Suppl 2):2772.

    • Search Google Scholar
    • Export Citation
  • 248.

    US Food and Drug Administration. Prescribing information. Tamiflu (oseltamivir phosphate). 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 249.

    US Food and Drug Administration. Prescribing information. Relenza (zanamivir) inhalation powder for oral inhalation. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021036s027lbl.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 250.

    US Food and Drug Administration. Influenza (flu) antiviral drugs and related information. Rockville, MD: 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm100228.htm. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 251.

    IsonMGHuiDSClezyK. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther2013;18:651661.

    • Search Google Scholar
    • Export Citation
  • 252.

    US Food and Drug Administration. Prescribing information. Rapivab (peramivir) for intravenous injection. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 253.

    BowdenRA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med1997;102:2730.

    • Search Google Scholar
    • Export Citation
  • 254.

    LjungmanP. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant2001;7(Suppl):5S7S.

    • Search Google Scholar
    • Export Citation
  • 255.

    WhimbeyEChamplinRECouchRB. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis1996;22:778782.

    • Search Google Scholar
    • Export Citation
  • 256.

    FeldmanSWebsterRGSuggM. Influenza in children and young adults with cancer: 20 cases. Cancer1977;39:350353.

  • 257.

    KempeAHallCBMacDonaldNE. Influenza in children with cancer. J Pediatr1989;115:3339.

  • 258.

    EltingLSWhimbeyELoW. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer1995;3:198202.

    • Search Google Scholar
    • Export Citation
  • 259.

    FioreAEUyekiTMBroderK. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep2010;59:162.

    • Search Google Scholar
    • Export Citation
  • 260.

    HarperSAFukudaKCoxNJBridgesCB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2003;52:18.

    • Search Google Scholar
    • Export Citation
  • 261.

    HamborskyJKrogerAWolfeS eds. Epidemiology and Prevention of Vaccine-Preventable Diseases13th edition. Washington DC: Centers for Disease Control and Prevention, Public Health Foundation; 2015.

    • Search Google Scholar
    • Export Citation
  • 262.

    Recommended adult immunization schedule: United States, 2012. Ann Intern Med2012;156:211217.

  • 263.

    EngelhardDAkovaMBoeckhMJ. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant2009;44:467470.

    • Search Google Scholar
    • Export Citation
  • 264.

    KrogerATAtkinsonWLMarcuseEKPickeringLK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2006;55:148.

    • Search Google Scholar
    • Export Citation
  • 265.

    DaviesJMLewisMPWimperisJ. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol2011;155:308317.

    • Search Google Scholar
    • Export Citation
  • 266.

    RubinLGSchaffnerW. Clinical practice. Care of the asplenic patient. N Engl J Med2014;371:349356.

  • 267.

    Recommended adult immunization schedule—United States 2010. Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention; 2010. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm. Accessed April 29 2016.

    • Search Google Scholar
    • Export Citation
  • 268.

    ZugmaierGToppMSAlekarS. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J2014;4:244.

    • Search Google Scholar
    • Export Citation
  • 269.

    BlumlSMcKeeverKEttingerR. B-cell targeted therapeutics in clinical development. Arthritis Res Ther2013;15(Suppl 1):S4.

  • 270.

    DiwakarLGorrieSRichterA. Does rituximab aggravate pre-existing hypogammaglobulinaemia?J Clin Pathol2010;63:275277.

  • 271.

    CasuloCMaraguliaJZelenetzAD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk2013;13:106111.

    • Search Google Scholar
    • Export Citation
  • 272.

    WalkerARKleinerARichL. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest2008;26:431433.

  • 273.

    IrieEShirotaYSuzukiC. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol2010;91:501508.

    • Search Google Scholar
    • Export Citation
  • 274.

    KasamonYLJonesRJBrodskyRA. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol2010;21:12031210.

    • Search Google Scholar
    • Export Citation
  • 275.

    NishioMFujimotoKYamamotoS. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol2007;137:349354.

    • Search Google Scholar
    • Export Citation
  • 276.

    OrtbalsDWLiebhaberHPresantCA. Influenza immunization of adult patients with malignant diseases. Ann Intern Med1977;87:552557.

  • 277.

    SommerALWachelBKSmithJA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract2006;12:143154.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4911 4912 774
PDF Downloads 1159 1159 160
EPUB Downloads 0 0 0